Go to the list of all blogs
Allana's Avatar
published in Blogs
Oct 24, 2026
TickeronGET DAILY SIGNALS
Boston Scientific (BSX) Maintains +2.3% Gain Over 30 Days After Guidance Reset

Boston Scientific (BSX) Maintains +2.3% Gain Over 30 Days After Guidance Reset

Key Takeaways

  • Boston Scientific shares have held a modest gain of about 2.3% over the trailing 30 days, moving from roughly $44.68 to $45.69, well below the threshold that signals a sharp price breakout.
  • The company beat Wall Street estimates in its latest quarter, yet lowered full-year 2026 guidance, reflecting slower WATCHMAN demand and U.S. electrophysiology share losses.
  • Analysts have trimmed price targets in recent weeks, though the broader consensus remains broadly constructive on the stock.
  • Slower near-term growth and a restructuring program are reshaping the investment narrative into 2027 and 2028.
  • Boston Scientific's next quarterly earnings report is expected in late October 2026 and will be a key catalyst for investor sentiment.
  • For more detail on valuation and expectations, explore the Price Targets, Earnings, and Forecast pages for BSX.
  • For additional insight, explore Trending AI Robots to see how algorithmic strategies are approaching the current market.

Where BSX Stands in the Market Today

Boston Scientific Corporation (BSX) is trading in the mid-$40s after a volatile stretch that has left the stock well below its 52-week high. Over the past 30 days, the shares have moved only slightly, a muted range that reflects investor caution following a guidance reset rather than a decisive directional trend. The stock remains positioned as a large-cap medical device leader, but near-term sentiment has been tempered by concerns about slowing demand in key cardiovascular franchises and a nervous backdrop across the broader medtech sector. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Boston Scientific's Business and Competitive Landscape

Boston Scientific develops and manufactures minimally invasive medical technologies across cardiology, cardiac rhythm management, electrophysiology, structural heart, peripheral interventions, endoscopy, urology, and neuromodulation. The company's diversified portfolio includes high-profile franchises such as the WATCHMAN left atrial appendage closure device and the FARAPULSE pulsed field ablation platform. With the majority of revenue generated in the United States and a growing international footprint, Boston Scientific competes against other large device makers, including Abbott Laboratories, while serving hospitals and physicians through a direct sales model. Investors follow the stock for its exposure to structural-heart and electrophysiology innovation, which have historically supported above-market growth.

Key Recent Developments for BSX

The most significant recent development has been the company's cautious guidance update. Boston Scientific reported second-quarter 2026 revenue of $5.44 billion, up 7.5% year over year, with adjusted earnings per share of $0.86 that beat consensus estimates. However, management lowered full-year 2026 guidance, citing an unexpected slowdown in the U.S. WATCHMAN market and greater-than-anticipated competitive share pressure in U.S. electrophysiology. The company now projects full-year adjusted earnings of $3.28 to $3.32 per share on reported sales growth of 5.5% to 6.5%.

In response, several analysts adjusted their ratings and price targets. Citi lowered its target to $48 while opening a downside catalyst watch, Barclays initiated coverage with an Equalweight rating and a $48 target, and Truist reduced its target to $51 from $57 while maintaining a Buy rating. Other firms, including BTIG, Leerink Partners, and Piper Sandler, reiterated Buy ratings with targets ranging from $55 to $60. The company also announced the promotion of Joe Fitzgerald to Chief Operating Officer effective January 2027 and detailed a restructuring program targeting roughly $500 million in run-rate cost savings by the end of 2029. From what I see, this restructuring could help stabilize margins over time.

2026 Outlook and What Investors Should Watch

Looking ahead, the central question for Boston Scientific is whether the current WATCHMAN and electrophysiology pressures represent a temporary transition or a longer stretch of slower growth. Management has indicated that key competitive responses, including the FARAWAVE Ultra platform and a next-generation defibrillator, are not expected until the second half of 2027, which means a meaningful electrophysiology recovery is unlikely before those launches. Investors should monitor quarterly organic revenue growth, the trajectory of WATCHMAN demand, and progress on the restructuring program. Macroeconomic factors, including hospital capital spending and procedural volumes, also remain important. The company's next earnings report will provide an updated read on whether third-quarter performance aligns with management's lowered expectations. I’m watching this closely as it could clarify the path forward.

Exploring AI-Driven Trading Insights

In my analysis, I frequently consult Tickeron’s Trending AI Robots to gauge how systematic strategies are positioning around healthcare stocks like this one. It provides a useful overview of top-performing bots without overwhelming options, helping me evaluate different risk profiles and time horizons in a straightforward way. This resource serves as a practical starting point when assessing algorithmic approaches to the current market environment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BSX

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


BSX in downward trend: price may drop because broke its higher Bollinger Band on October 19, 2026

BSX broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 33 similar instances where the stock broke above the upper band. In 20 of the 33 cases the stock fell afterwards. This puts the odds of success at 61%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BSX as a result. In 50 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.

The Moving Average Convergence Divergence Histogram (MACD) for BSX turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 26 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.

BSX moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BSX crossed bearishly below the 50-day moving average on November 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in 201 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. BSX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.485) is normal, around the industry mean (4.142). P/E Ratio (17.169) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.618) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a maker of medical devices

Industry MedicalNursingServices

Industry
Medical Specialties
Address
300 Boston Scientific Way
Phone
+1 508 683-4000
Employees
59000
Web
https://www.bostonscientific.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.